12.25

4.74% -0.61

Eyepoint Inc (EYPT)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Eyepoint Inc stock is traded at $12.25, with a volume of 1.71M. It is down -4.74% in the last 24 hours and down -14.34% over the past month. EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.

Previous Close:

$12.86

Open:

$12.81

24h Volume:

1.71M

Relative Volume:

1.44

Market Cap:

$1.03B

Revenue:

$7.62M

Net Income/Loss:

$-271.60M

P/E Ratio:

-3.4982

EPS:

-3.5018

Net Cash Flow:

$-271.54M

1W Performance:

+0.49%

1M Performance:

-14.34%

6M Performance:

-9.39%

1Y Performance:

+24.75%

1-Day Range:

$12.04

$12.83

1-Week Range:

$11.55

$13.03

52-Week Range:

$9.40

$19.11

Eyepoint Inc Stock (EYPT) Company Profile

Name

Eyepoint Inc

Sector

Healthcare (1079)

Industry

Biotechnology (598)

Phone

617-926-5000

Address

480 PLEASANT STREET, WATERTOWN, MA

Employee

214

Twitter

@eyepointpharma

Next Earnings Date

2026-08-05

Latest SEC Filings

EYPT's Discussions on Twitter

Compare EYPT vs VRTX, REGN, ARGX, RVMD, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
EYPT Eyepoint Inc	12.25	1.04B	7.62M	-271.60M	-271.54M	-3.5018
VRTX Vertex Pharmaceuticals Inc	477.10	121.57B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	762.63	69.95B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	853.82	55.61B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	187.53	39.98B	742.00K	-1.37B	-1.07B	-7.0731
ONC Beone Medicines Ltd Adr	316.01	33.81B	5.76B	514.49M	1.10B	4.4813

Eyepoint Inc Stock (EYPT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jun-17-25	Initiated	RBC Capital Mkts	Outperform
Jan-07-25	Initiated	Citigroup	Buy
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Aug-28-24	Initiated	Jefferies	Buy
Jan-22-24	Initiated	JP Morgan	Overweight
Nov-02-23	Initiated	Mizuho	Buy
Apr-21-23	Initiated	Robert W. Baird	Outperform
Jul-07-22	Initiated	Chardan Capital Markets	Buy
Mar-01-21	Initiated	Cowen	Outperform
Jan-28-21	Initiated	Cantor Fitzgerald	Overweight
Apr-06-20	Downgrade	B. Riley FBR	Buy → Neutral
Nov-04-19	Resumed	Laidlaw	Buy
Sep-12-19	Initiated	Guggenheim	Buy

View All

Eyepoint Inc Stock (EYPT) Latest News

Jul 28, 2026

U.S. cracks down on EyePoint over alleged kickbacks, company to pay $4.66 million settlement - Peoples Gazette Nigeria

Jul 28, 2026

Did EyePoint's (EYPT) Federal Settlement and 5‑Year Integrity Deal Just Reframe Its Risk Profile? - simplywall.st

Jul 28, 2026

EYPT|EyePoint Pharmaceuticals Inc|Price:12.405|Chg%:+0.215 - TradingKey

Jul 28, 2026

Jul 27, 2026

EyePoint Pharmaceuticals Inc (EYPT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey

Jul 27, 2026

EyePoint Pharmaceuticals Inc (EYPT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey

Jul 27, 2026

EyePoint Pharmaceuticals Inc - TradingKey

Jul 27, 2026

Jul 26, 2026

EyePoint, Inc. Revenue Breakdown – NASDAQ:EYPT - TradingView

Jul 26, 2026

Jul 25, 2026

EyePoint Pharmaceuticals Inc (EYPT) Valuation: PE, PB & Fair Value Analysis - TradingKey

Jul 25, 2026

EYPT|EyePoint Pharmaceuticals Inc|Price:12.190|Chg%:-0.280 - TradingKey

Jul 25, 2026

EyePoint Pharmaceuticals Inc (EYPT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey

Jul 25, 2026

EyePoint Pharmaceuticals Inc (EYPT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey

Jul 25, 2026

EyePoint Pharmaceuticals Inc (EYPT) Institutional Confidence - TradingKey

Jul 25, 2026

Jul 24, 2026

EyePoint Pharmaceuticals Inc (EYPT) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey

Jul 24, 2026

Jul 23, 2026

RBC Capital Maintains EyePoint(EYPT.US) With Buy Rating, Maintains Target Price $37 - Moomoo

Jul 23, 2026

Jul 22, 2026

J.P. Morgan Maintains EyePoint(EYPT.US) With Buy Rating, Cuts Target Price to $30 - Moomoo

Jul 22, 2026

EYPT (NASDAQ: EYPT) plans sale of 1,235 common shares from options - Stock Titan

Jul 22, 2026

EYPT (NASDAQ: EYPT) affiliate plans sale of 1,235 common shares via Form 144 - Stock Titan

Jul 22, 2026

Jul 21, 2026

Form 144 EyePoint For: 21 July By Investing.com - Investing.com South Africa

Jul 21, 2026

EYPT (NASDAQ: EYPT) plans brokered sale of 421,235 shares valued at $5.5M - Stock Titan

Jul 21, 2026

Price to earnings forward of EyePoint, Inc. – MUN:PV3B - TradingView

Jul 21, 2026

Jul 20, 2026

Drug company to pay $4.7M after admitting it paid providers to use its product - Yahoo Finance

Jul 20, 2026

Watertown Company Will Pay Nearly $4.7 Million to Resolve False Claims Act Allegations - watertownmanews.com

Jul 20, 2026

Jul 19, 2026

EyePoint to pay $4.6M to settle with DOJ over kickback claims - MSN

Jul 19, 2026

Jul 18, 2026

EyePoint Pharmaceuticals Agrees to Pay $4.6 Million to Settle False Claims Act Allegations - Markets Herald

Jul 18, 2026

EyePoint, Inc. Settles DOJ False Claims Act Case and Implements Comprehensive Compliance Program - Minichart

Jul 18, 2026

Price-Driven Insight from (EYPT) for Rule-Based Strategy - Stock Traders Daily

Jul 18, 2026

EyePoint Pharmaceuticals Agrees to Settle US False Claims Act Allegations - Moomoo

Jul 18, 2026

Jul 17, 2026

EyePoint to Pay $4.7M to Resolve Allegations of False Claims Act Violations - Moomoo

Jul 17, 2026

Eyepoint Enters Settlement Agreement With DOJ, OIG-HHS, And DHASEC Filing - TradingView

Jul 17, 2026

EyePoint Pharmaceuticals (EYPT) Settles for $4.6M Over Kickback Allegations - GuruFocus

Jul 17, 2026

EyePoint (NASDAQ: EYPT) signs five-year federal Corporate Integrity Agreement - Stock Titan

Jul 17, 2026

United States: EyePoint Pharmaceuticals To Pay $4.6 Million To Resolve False Claims Act Allegations - The St Kitts Nevis Observer

Jul 17, 2026

EyePoint Agrees To Pay $4.65M To U.S. Government In FCA Suit Settlement - Mealey's

Jul 17, 2026

EyePoint to pay $4.6M to settle with DoJ over kickback claims - Seeking Alpha

Jul 17, 2026

Jul 16, 2026

Stifel Maintains EyePoint(EYPT.US) With Buy Rating, Maintains Target Price $40 - Moomoo

Jul 16, 2026

EYPT Initiated Coverage by Stifel -- Buy Rating with $40 Price T - GuruFocus

Jul 16, 2026

This Rambus Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Benzinga

Jul 16, 2026

EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - The Manila Times

Jul 16, 2026

Two New EyePoint Employees Receive Options for 63,500 Shares - Stock Titan

Jul 16, 2026

Jul 15, 2026

Stifel initiates EyePoint stock with buy rating on retinal drug potential By Investing.com - Investing.com South Africa

Jul 15, 2026

Stifel initiates EyePoint stock with buy rating on retinal drug potential - Investing.com Nigeria

Jul 15, 2026

Stifel Initiates EyePoint(EYPT.US) With Buy Rating, Announces Target Price $40 - Moomoo

Jul 15, 2026

Jul 14, 2026